Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04444752 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Connect Biopharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
NCT04444752 is a Phase 2 study that has completed, run by Connect Biopharm. The registered enrollment target is 226 participants.
The verdict
NCT04444752, a Phase 2 study, has completed, sponsored by Connect Biopharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of CBP-201 in adult subjects with moderate to severe atopic dermatitis.
Interventions
- DRUG placebo
- DRUG CBP-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2020-07-17 |
| Est. Completion | 2021-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04444752
The ClinicalTrials.gov registry entry for NCT04444752 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Connect Biopharm, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT04444752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04444752 about?
NCT04444752 is a clinical study titled "A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis". This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of CBP-201 in adult subjects with moderate to severe atopic dermatitis.
What is the current status of trial NCT04444752?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2020-07-17. Estimated completion is 2021-09-22.
What interventions are being tested in trial NCT04444752?
The interventions under investigation include: placebo (DRUG), CBP-201 (DRUG).
Who is sponsoring clinical trial NCT04444752?
This trial is sponsored by Connect Biopharm, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.